LindseyRobertBadenMD

Infectious Disease • Boston, MA

Associate Professor of Medicine, Brigham and Women's Hospital

Join to view full profile

Are you Dr. Baden?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 120 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
75 Francis St
# Brigham
Boston, MA 02115
Phone+1 617-732-8881

Summary

Dr. Lindsey Baden, MD is an infectious disease specialist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, Rhode Island, and Maine. He is affiliated with Brigham and Women's Hospital and Dana-Farber Cancer Institute.

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Infectious Disease, 1995 - 1999
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1992 - 1995
Albert Einstein College of MedicineClass of 1992

Certifications & Licensure

ME State Medical License Current
MA State Medical License 1994 - 2025
RI State Medical License 2022 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Start of enrollment: 2003 Nov 01
Completed
Phase 3
Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults
Completed
Phase 1
Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults Start of enrollment: 2008 Feb 01
Completed
Phase 1
Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults Start of enrollment: 2009 Feb 08
Completed
Phase 1
Efficacy of Post-operative Antibiotic Prophylaxis for Thoracic Surgery Requiring Tube Thoracostomy Start of enrollment: 2008 Mar 01
Completed
Not Applicable
Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins Start of enrollment: 2010 Jan 01
Completed
Phase 1
Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults Start of enrollment: 2010 Jul 01
Completed
Phase 1
Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults Start of enrollment: 2010 Oct 01
Completed
Phase 1
Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults
Withdrawn
Phase 1
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant Start of enrollment: 2015 Nov 05
Active, not recruiting
Phase 2
Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants Start of enrollment: 2019 Aug 26
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials.
Holly Janes, Leigh H Fisher, Jia Jin Kee, Lalitha Parameswaran, Paul A Goepfert
The Journal of Infectious Diseases. 2024-12-16
Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial.
Dean Follmann, Xiaowei Wang, Lindsey R Baden, Hana M El Sahly, Brandon Essink
Open Forum Infectious Diseases. 2024-12-01
The BNT162b2 mRNA vaccine demonstrates reduced age-associated T1 supportand.
Byron Brook, Abhinav Kumar Checkervarty, Soumik Barman, Cali Sweitzer, Anna-Nicole Bosco
Iscience. 2024-11-15

Press Mentions

I’m Worried About Going to Hospitals Without a MaskMay 10th, 2023
All Thumbs up from FDA Panel for Bacterial Pneumonia TherapyApril 18th, 2023
Advisors to the US Food and Drug Administration (FDA) Recommend Full Approval of Pfizer’s Covid Drug PaxlovidMarch 17th, 2023
Join now to see all